No More Fake Paneer: Maharashtra FDA Mandates Disclosure of Cheese Analogues on Menus, Bills from 1st May

Moneylife Digital Team 23 April 2026

Life

In a significant consumer protection move, the food and drug administration (FDA) in Maharashtra has directed all food establishments across the state to clearly disclose the use of paneer or cheese analogues in their dishes from 1st May.

The directive applies to restaurants, hotels, caterers and fast-food vendors, requiring them to explicitly mention the use of such substitutes on menus, display boards and even customer bills.

The order, issued by food safety commissioner Shridhar Dubey-Patil, comes in response to a surge in consumer complaints about eateries allegedly passing off analogue products as genuine paneer or cheese.

Mandatory Disclosure across Platforms

According to FDA, any establishment using cheese analogue or paneer analogue must prominently declare it across all customer-facing platforms, including printed menus, electronic displays and invoices.

The regulator has also extended the compliance requirement to manufacturers and suppliers, directing them to ensure that packaging and labelling clearly indicate the true nature of the product and do not mislead consumers, in line with provisions of the Food Safety and Standards Authority of India regulations and the Food Safety and Standards Act, 2006.

Authorities have set 30 April 2026 as the deadline for businesses to update menus and labelling, following which enforcement action and inspections will begin statewide.

What Are Cheese Analogues?

Unlike traditional paneer, which is made entirely from milk, cheese analogues are manufactured using edible vegetable oils, starches, emulsifiers and other non-dairy ingredients. While they may resemble paneer or cheese in appearance and taste, their composition and nutritional profile differ significantly.

The FDA clarified that such products are not unsafe for consumption, but stressed that the issue at hand is transparency and the consumer’s right to make informed choices.

Trigger: Consumer Complaints and Mislabelling

Food safety officials say the move was prompted by multiple complaints about food businesses selling dishes labelled as 'paneer' while using cheaper substitutes without disclosure.

Officials noted that such practices violate consumer rights under food safety laws, particularly provisions that mandate accurate representation of food products.

“Consumers have the right to know what they are eating,” officials say, adding that misleading labelling erodes trust and undermines fair trade practices.

Strict Enforcement and Penalties

FDA has warned that non-compliance will invite strict action under the Food Safety and Standards Act, including penalties, prosecution and possible suspension of licences.

State-wide inspection drives are expected to begin after the 1 May 2026 deadline to ensure adherence.

Officials have also highlighted that the directive forms part of a broader crackdown on misbranding, adulteration and deceptive practices in the food industry.

Responsibility on Consumers

Alongside enforcement measures, FDA has urged consumers to remain vigilant. Customers are advised to check menus carefully while dining out, look for clear mention of 'analogue' products, and seek clarification where necessary.

For packaged products, buyers have been asked to read labels closely and verify whether the product is milk-based or a substitute.

The latest directive is aimed at bringing greater transparency to Maharashtra’s rapidly expanding food services sector, ensuring that consumers receive accurate information about what they are paying for.

With enforcement set to begin from 1st May, eateries across the state are now under pressure to revise menus and practices, marking a shift towards stricter accountability in the food business.

Comments

User

Life

Weight-loss, Diabetes Drugs GLP-1: Govt Flags Serious Health Risks, Tightens Rules amid Rising Misuse and Safety Concerns

Moneylife Digital Team 01 April 2026

The Indian government has issued a strong warning against the misuse of glucagon-like peptide-1 receptor agonists (GLP-1) drugs, widely used for treating type-2 diabetes and obesity, while stepping up regulatory action to curb their...

Life

Beyond Surgery: Why India Fails Spinal Cord Injury Patients after Hospital Discharge

Dr Ketna L. Mehta, 31 March 2026

India’s healthcare system has made significant advances in specialised and tertiary care. However, for individuals living with spinal cord injuries, medical intervention is only the beginning of a far more complex and often...